Evidence map›Paper›PMID 41440237›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

STAT2 Promotes Tumor Growth in Colorectal Cancer Independent of Type I IFN Receptor Signaling.

Jorge Canar, Madeline Bono, Amy Alvarado, Michael Slifker, Giovanni Sitia, Ana M Gamero

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jorge CanarDepartment of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
Madeline BonoDepartment of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.ORCID 0009-0006-7871-1488
Amy AlvaradoDepartment of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
Michael SlifkerBiostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Giovanni SitiaDivision of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.ORCID 0000-0003-1024-9128
Ana M GameroDepartment of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.ORCID 0000-0001-7843-1415

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Eric Andrew Ross · 1985 to 2026
$138.8M
TUFCCC/HC Regional Comprehensive Cancer Health PartnershipU54CA221705 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI Joel Erblich, Jennifer S Ford · 2018 to 2026
$16.3M
Molecular Biology and Genetics: Signaling, Epigenetics and Genome MaintenanceT32GM142606 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI Xavier Grana, Kelly A Whelan · 2021 to 2026
$1.5M
Investigation of STAT2 Signaling in the tumor microenvironmentR03CA273613 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI GAMERO, ANA M · 2023 to 2024
$229k
NCI NIH HHS P30 CA006927NCI NIH HHS R03 CA273613NCI NIH HHS R03 CA273613-01A1NCI NIH HHS U54 CA221705NIGMS NIH HHS GM142606-01NIGMS NIH HHS T32 GM142606
6 · The paper itself

Abstract

The role of Signal Transducer and Activator of Transcription 2 (STAT2) in cancer remains poorly understood. STAT2 is a key mediator of type I interferon (IFN) signaling, activating the expression of IFN-stimulated genes with antiviral and antiproliferative effects. However, emerging evidence suggests that STAT2 can also promote tumor growth. Here, we show that high STAT2 mRNA expression in colon cancer tumors correlates with reduced overall survival in patients. In preclinical models, deletion of STAT2 in tumor cells suppressed tumor growth, whereas STAT2 overexpression enhanced tumor growth, supporting its pro-tumorigenic role. To determine whether this function depends on type I IFN receptor (IFNAR1) signaling, we generated IFNAR1 knockout (IFNAR1 KO) colon carcinoma cells and compared their growth with parental and STAT2-deficient (STAT2 KO) tumor cells. Loss of type I IFN signaling was confirmed by western blot and qPCR analyses. In vitro, IFNAR1 KO and STAT2 KO tumor cells proliferated at similar rates. However, in xenograft tumor transplantation models, IFNAR1 KO cells formed larger tumors while STAT2 KO tumor cells formed smaller ones compared to parental tumor cells. These findings indicate that STAT2 promotes colorectal cancer growth through mechanisms independent of IFNAR1 signaling.

Indexed as

Colorectal NeoplasmsReceptor, Interferon alpha-betaSTAT2 Transcription FactorAnimalsCell Line, TumorCell ProliferationFemaleHumansMaleMiceSignal TransductionIFNAR1 protein, humanReceptor, Interferon alpha-betaSTAT2 protein, humanSTAT2 Transcription FactorcancercolorectalinterferonSTAT2TCGAtumor

Identifiers

PMID41440237
PMCPMC12732172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.